ADAGIO THERAPEUTICS INC (ADGI) Stock Price, Quote, News and Overview
NASDAQ:ADGI - Nasdaq - US00534A1025 - Common Stock - Currency: USD
ADGI Quote, Performance and Key Statistics
4.64
+0.04 (+0.87%)
The current stock price of ADGI is 4.64 USD. In the past month the price increased by 16.29%. In the past year, price decreased by -90.98%.
ADGI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ADGI
Company Profile
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The firm has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.
Company Info
ADAGIO THERAPEUTICS INC
1601 Trapelo Road, Suite 178
Waltham MASSACHUSETTS US
Employees: 101
Company Website: https://adagiotx.com/
Phone: 17818190080.0
ADAGIO THERAPEUTICS INC / ADGI FAQ
What is the stock price of ADAGIO THERAPEUTICS INC today?
The current stock price of ADGI is 4.64 USD. The price increased by 0.87% in the last trading session.
What is the ticker symbol for ADAGIO THERAPEUTICS INC stock?
The exchange symbol of ADAGIO THERAPEUTICS INC is ADGI and it is listed on the Nasdaq exchange.
On which exchange is ADGI stock listed?
ADGI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADAGIO THERAPEUTICS INC stock?
9 analysts have analysed ADGI and the average price target is 3.91 USD. This implies a price decrease of -15.73% is expected in the next year compared to the current price of 4.64. Check the ADAGIO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADAGIO THERAPEUTICS INC worth?
ADAGIO THERAPEUTICS INC (ADGI) has a market capitalization of 504.74M USD. This makes ADGI a Small Cap stock.
How many employees does ADAGIO THERAPEUTICS INC have?
ADAGIO THERAPEUTICS INC (ADGI) currently has 101 employees.
What are the support and resistance levels for ADAGIO THERAPEUTICS INC (ADGI) stock?
ADAGIO THERAPEUTICS INC (ADGI) has a support level at 4.47 and a resistance level at 4.71. Check the full technical report for a detailed analysis of ADGI support and resistance levels.
Should I buy ADAGIO THERAPEUTICS INC (ADGI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADGI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADGI, evaluating the profitability, health, valuation and growth aspects
- ADAGIO THERAPEUTICS INC (ADGI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADAGIO THERAPEUTICS INC (ADGI) Sales and EPS estimates to see what analysts future expectations are.
- ADAGIO THERAPEUTICS INC (ADGI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADAGIO THERAPEUTICS INC (ADGI) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADAGIO THERAPEUTICS INC (ADGI) Stock Chart to make your own analysis
- ADAGIO THERAPEUTICS INC (ADGI) Latest news and press-releases to stay up to date.
Does ADAGIO THERAPEUTICS INC (ADGI) stock pay dividends?
ADGI does not pay a dividend.
What is the Price/Earnings (PE) ratio of ADAGIO THERAPEUTICS INC (ADGI)?
ADAGIO THERAPEUTICS INC (ADGI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.15).
ADGI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ADGI. When comparing the yearly performance of all stocks, ADGI turns out to be only a medium performer in the overall market: it outperformed 60.44% of all stocks.
ADGI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADGI. While ADGI seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADGI Financial Highlights
Over the last trailing twelve months ADGI reported a non-GAAP Earnings per Share(EPS) of -3.15. The EPS decreased by -74.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.89% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ADGI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 47% to ADGI. The Buy consensus is the average rating of analysts ratings from 9 analysts.